Objective. There is limited evidence on effectiveness of calcium and vitamin D on dysmenorrhea. The authors aimed to determine the effect of combined calcium-vitamin D and calcium-alone on pain intensity and menstrual blood loss in women with primary dysmenorrhea.
Methods. Participants were randomized into three groups: receiving one tablet/day of 1000 mg calcium 1 5000 IU vitamin D3, calcium-alone 1000 mg, or matched placebo, from 15th cycle day until menstrual pain disappearance in the following cycle, for three cycles. Pain intensity and menstrual blood loss were assessed one cycle before, three cycles under, and one cycle following intervention using 10-cm visual analog scale and pictorial blood loss assessment chart, respectively. The groups were compared using repeated measures ANOVA.
Results. Time after intervention and interaction of time with group had no significant effects on the outcomes. Compared to the placebo group, mean pain intensity was lower in the both calcium-vitamin D (adjusted difference 20.7, 95% confidence interval 21.6 to 0.3) and calcium-alone (21.6, 22.6 to 20.6) groups, but the difference was statistically significant only in the calcium-alone group. Menstrual blood loss was not significantly different in the either calcium-vitamin D (24.7, 221.9 to 12.4) or calcium-alone (20.4 , 217.4 to 16.4) groups compared to placebo.
Conclusions. Intake of the calcium-alone was effective in reducing menstrual pain intensity. The results could not indicate significant effects of calcium-vitamin D on the pain or any of the interventions on menstrual blood loss.
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Introduction
Primary dysmenorrhea is a common gynecological disorder affecting more than 50% of women of reproductive age [1] . In a population-based study in a capital city of Iran, the prevalence of moderate and severe dysmenorrhea was reported as 28% and 22% respectively, and younger women experienced greater pain [2] .
Primary dysmenorrhea is related to the normal process of menstruation. Its etiology has been not precisely understood, but most of its symptoms can be explained by the action of endometrial prostaglandins. It is similar in nature to labor pain, and often accompanied by supra-pubic cramps, backache and pain radiating to the thigh [1] . Significant positive relationships have been reported between severity of dysmenorrhea and prolonged [3] and abnormal [4] uterine bleeding. Reduced health-related quality of life [5] , absence from school or work, poor concentration [6] , and limitation of other daily activities [7] are among reported problems associated with dysmenorrhea.
Various methods are used in treatment of dysmenorrhea. Non-steroidal anti-inflammatory drugs (NSAIDs), the most common treatment, have complications such as peptic ulcer, hepatic, and renal disorders, and skin allergies [8] . Hormonal contraceptives are also considered as effective treatment options. However, some women do not wish to use contraceptives for the relief of pain and some have religious or cultural conflicts with the use of these medications [9] . Therefore, many women use other methods for treatment of dysmenorrhea, including vitamins and mineral supplements, and herbal remedies [10] .
Studies show that metabolism and absorption of vitamins and minerals may play a major role in development and treatment of menstrual disorders [10] . Calcium is able to regulate capability of muscle cells in response to nervous stimuli, and can be considered as a stabilizer. Reduced calcium has been suggested to cause muscle spasm and contraction [11] . Calciferol (the active form of vitamin D) may regulate prostaglandin levels [12] .
More than 70% of dietary calcium is provided by dairy products [13] , prompting researchers to study the relationship between dairy product intake and severity of dysmenorrhea in observational studies. They have reached contradictory results, including significant positive [14] and negative [15] relationships between the variables. In a previous clinical trial, we demonstrated the effects of combined calcium-magnesium and calcium-alone supplements in reducing pain intensity and duration of menstrual bleeding in students with primary dysmenorrhea [16] . Also, the effect of vitamin D administration on reducing severity of dysmenorrhea has been shown in limited studies [17, 18] .
Given the high prevalence of inadequate calcium intake [19] and vitamin D deficiency, especially among the Middle Eastern women, and moderate to severe deficiency in Iran [20, 21] , with subsequent transient loss of ionized calcium [22] , it is possible that supplementation of calcium\vitamin D might reduce severity of dysmenorrhea .
Because of the limited number of studies with some contradictory results in this area, and no reports of adverse effects caused by the intervention, we aimed to determine the effects of combined calcium-vitamin D and calcium-alone on pain intensity and menstrual blood loss (as primary outcomes), and on quality of life, satisfaction with treatment, and analgesic (ibuprofen) intake (as secondary outcomes) in women with primary dysmenorrhea.
Methods

Study Design and Participants
This randomized placebo-controlled trial with three parallel arms was conducted on 85 single students aged 18 to 32 years living in all three female dormitories of Tabriz University of Medical Sciences, Tabriz-Iran. About 2000 non-native female students from different parts, mostly north-west, of the country and from all medical sciences disciplines at various levels from associate diplomas to PhDs live in the dormitories. Inclusion criteria were: painful and relatively regular menstruation (duration of menstrual cycle 21 to 35 days) in recent six cycles with maximum pain intensity between 5.0 and 9.1 according to 10-cm visual analog scale (VAS), with primary dysmenorrhea pain features (such as crampy and spasmodic pain in lower abdomen radiating to the back and thighs, which begins just before or as menstrual bleeding begins, and gradually diminishes over 1 to 3 days). Those with any of the following were excluded from the trial: known lactose intolerance or chronic disease (including epilepsy, gastrointestinal, cardio-vascular or renal diseases); taking oral contraceptives, or regularly taking mineral or vitamin supplements in the past 3 months (due to their possible interference with the interventions); willing to or already taking part in other clinical trials.
Intervention
Tablets were made from appropriate excipients used in tableting process, including lactose, starch, and microcrystalline cellulose. Sodium glycolate was used as disintegrant, and magnesium stearate in quantities of 1% as lubricant to prevent sticking of tablet to the punch and dies. Each calcium-vitamin D tablet contained Zarei et al.
1000 mg of calcium carbonate and 5000 units of vitamin D, and each calcium-alone tablet contained 1000 mg of calcium carbonate. Matched placebo tablets had no medication. Following wet granulation process, tablets were pressed in the tablet machine using capsuleshaped punches, so that all tablets looked exactly the same with no apparent difference, and had acceptable properties in terms hardness, friability, and release time. The tablets were made under supervision of a pharmacist colleague in pharmaceutical technology laboratories of school of pharmacy, Tabriz University of Medical Sciences.
Each participant received three packets of 20 tablets (each packet for one cycle intake), as well as written and verbal explanations about how to use the tablets. Participants were asked to take one tablet a day with a glass of water from 15th day of menstrual cycle until disappearance of menstrual pain in the following cycle.
To be able to control confounding effect of using other treatment methods, we gave all participants an identical pack of ibuprofen (ten 400 mg gelofen pearl) produced by Dana Pharmaceuticals, Tabriz, Iran (the most commonly used method for the pain relief by the participants), to take for relief of menstrual pain, if required, during the five study cycles. We emphasized the participants not to use any other medicinal or non-medicinal methods to reduce dysmenorrhea.
Participants were asked to record the study tablets and the ibuprofen used in a diary. The remaining unused study tablets and the ibuprofen were returned and counted in monthly visits. To emphasize regular use and record of the study drugs, participants were contacted on the phone every other week.
Outcomes and Data Collection Tools
The pain intensity and menstrual blood loss were considered as primary outcomes, and were assessed using VAS and pictorial blood loss assessment chart (PBLAC), respectively, over one cycle pre-intervention (run-in period), three cycles of receiving supplements/placebo, and one cycle following the intervention.
The pain VAS is a 10-cm continuous horizontal line, anchored by two descriptors, 0 (no pain) at one end and 10 (worst imaginable pain) at the other end. This scale has been widely used in diverse adult populations, and its validity and reliability have been confirmed [23] . Participants recorded average pain intensity experienced over the last 24 hours at the end of each day from the day menstrual pain begins (at most 1 day prior to onset of menstruation) until 5th day of the cycle. As menstrual pain typically last less than 3 days with highest pain intensity in different days of the cycles (from the day just before menstrual bleeding begins until the 5th day, usually in the first 2 days of the cycle) [24] , the mean of the two highest pain intensity reported at each cycle was considered as pain intensity at the cycle.
PBLAC shows the number of menstrual days in the horizontal row, and sanitary pads stained mildly, moderately, completely, with blood clots, and flooding in vertical column. Scores considered for the stained pads were as follows: mildly stained scored 1, moderately stained scored 5, and completely stained scored 20, small clot scored 1, large clot scored 5, and flooding blood scored 5. Total score is indicative of bleeding amount in cubic centimeter [25] . It is shown that PBLAC scores and the amount of menstrual blood loss measured by hematinic phosphatase (as a gold standard) are significantly correlated (Spearman r ¼ 0.600) and this test can be used in clinical practice for the follow up and treatment decisions [26] . Identical disposable pads were distributed among participants for using during the five study cycles.
Secondary outcomes included the number of analgesics (ibuprofen) used in each cycle (1 day before onset of menstruation until the 5th day of cycle), frequency of side-events during the intervention, patient satisfaction with the medications used over three intervention cycles and one post-intervention cycle, and also health-related quality of life score during the third intervention cycle.
The number of ibuprofen taken was recorded by the participants once a day on the diary. The diary also included a table with a list of possible side-effects; nausea, vomiting, headache, diarrhea, constipation, dry mouth, and an option to mention other side-effects experienced, which were completed by the participants on the 7th day of each intervention cycle. Participant satisfaction with the intervention was assessed using one 5-points Likert question (very satisfied, satisfied, neither satisfied nor dissatisfied, dissatisfied, very dissatisfied) in the diary on the 7th day of each intervention cycle.
To assess health-related quality of life, SF-36 questionnaire was completed by the participants on the 7th day of the pre-intervention cycle and again the third cycle under-intervention. This self-report 36-item questionnaire has eight subscales, with two summary measures of physical and mental health components, and a range of score from 0 to 100 (the higher score, the better condition). Physical health component score is constructed by combination of four subscales of physical functioning, role physical, bodily pain, and general health, and mental health component score is constructed by four subscales of social functioning, role emotional, mental health, and vitality. Validity and reliability of this questionnaire have been already confirmed for the Iranian population [27] .
Daily dietary calcium intake (as possible confounding variable) was determined using a food frequency questionnaire (FFQ) including the foods containing the highest amount of calcium. We asked participants to report average portions used over the two prior weeks, which is used to calculate calcium intake in milligrams. Those Calcium and Vitamin D for Dysmenorrhea with intake of less than 1000 mg of calcium per day were considered to have calcium deficiency [28] .
To determine content validity of questions about demographic characteristics, the FFQ, and side-effects, the questionnaire was reviewed by 10 experts from various disciplines including midwifery, nutrition, and obstetrics and gynecology, and necessary modifications were made according to feedbacks received.
Sampling and Randomization
Participant recruitment was started after study proposal was approved scientifically by the research committee of school of nursing and midwifery, and ethically by the ethics committee of research and technology deputy (code No. 92145) of Tabriz University of Medical Sciences and after registration of study in Iranian registry of clinical trials site (IRCT201402043706N21).
To select participants, the investigator (SZ, first author) visited students in their dorms and explained study objective and method, with emphasizing on the follow-up duration, and asked potentially eligible volunteer students to complete the eligibility forms. One-hundredtwenty eligible students after signing written informed consent forms and completing demographic questions and the FFQ entered the run-in period of study. They were asked to record prospectively their menstrual pain intensity and bleeding amount during the following cycle (pre-intervention), and to complete SF-36 inventory on the 7th day of the cycle. Out of them, 85 students who had good cooperation (followed the instructions and completed the questionnaire and diary precisely) and were willing to carry on were randomly allocated into two intervention groups and one placebo group.
Randomization sequence was determined using a computer-generated list of random numbers with a 1:1:1 allocation ratio using random block sizes of 3 and 6. For each participant, three packets of 20 study tablets were put in identical consecutively numbered packs according to the allocation sequence. Allocation sequence and packaging were prepared by someone not involved with collection and analysis of data. Therefore, the participants, the persons involved in the recruitment and data collection, also the analyst were all unaware of the group each person assigned to.
Sample Size and Data Analysis
Given mean score of menstrual pain intensity of 5.2 (SD 2.2) reported by Nezamivand et al. [16] , and anticipated 30% reduction in the mean score due to intervention (M 2 ¼ 3.6), a ¼ 0.05, and b ¼ 0.2, and considering possible 10% withdrawals, sample size was determined 30 per each group. Given mean score of menstrual blood loss of 48 (SD 13) obtained in the same study, and a ¼ 0.05, this sample size can detect minimum 30% reduction in mean score of the blood loss due to intervention.
Normality of data distribution was confirmed using K-S test. Repeated measures ANOVA was used to compare the groups in terms of pain intensity and menstrual bleeding, and ANCOVA to compare quality of life scores adjusted for baseline values and dietary calcium received. Sidak was used to adjust for the multiple comparisons. Satisfaction with treatment was compared using trend Chi-square. Data were analyzed using SPSS-14 software; P < 0.05 was considered significant.
Results
Participation recruitment lasted from March to August 2013, and follow-up ended in November 2013. Because another clinical trial was being conducted concurrently on the same population and it was difficult to access eligible students who cooperated, sample size 90 was reduced to 85 (29 in calcium-vitamin D group, and 28 in each of the other two groups). One participant from the calcium-alone group was not accessible after one-cycle intervention, but the other two groups were fully followed up ( Figure 1 ).
We had decided to stratify participants by adequacy/inadequacy (Less or more than 1000 mg/day) of calcium intake. However, this was not possible because according to the FFQ, nearly all participants (except 9) were found to have calcium deficiency. Therefore, we decided to enter amount of daily calcium intake calculated by the FFQ as a potentially confounding factor in all the group comparisons for the outcomes.
No significant difference was observed between the groups in terms of socio-demographic characteristics. Mean (SD) age of participants was 23.6 (3.2) years, BMI was 21.8 (2.9) kg/m 2 , and daily dietary calcium intake was 564 (365) mg. Just under half (46%) of the participants reported being exposed to sunlight for less than 15 minutes/day, and about three-quarters (72%) reported no regular exercise, and none smoked. More than half (58%) reported menstrual pain relief by massage or body movement, 40% reported onset of pain a few hours before menstrual bleeding, and 66% reported reduced pain one or two days after bleeding (Table 1) .
Mean (SD) number of study drug used in the first, second, and third cycles was 13.2 (4.6), 13.2 (5.3), and 13.2 (5.5) in the calcium-vitamin D group; 13.0 (4.4), 12.8 (5.2), and 11.1 (5.9) in the calcium-alone group; and 14.3 (2.9), 11.0 (5.4), and 9.3 (5.8) in the placebo group, respectively. There were no significant differences between the groups in terms of the number of the tablets used in any of the cycles, except in the third cycle of intervention that was lower in the placebo group compared to calcium-vitamin D group (P ¼ 0.014).
During the run-in period (the cycle just prior to the intervention cycles), about one third (35%) reported menstrual pain intensity of greater than 7.0. At this cycle, there were no statistically significant differences between the study groups in terms of mean score of any of the baseline values; the pain intensity [mean score of all participants 6.1 (SD Time after intervention, as well as interaction of time with group, had no significant effects on the primary outcomes (menstrual pain intensity and menstrual blood loss score). Hence, overall effects of the interventions were reported over three cycles under-intervention and the following cycle.
Compared to the placebo group, mean pain intensity was lower in both calcium-vitamin D group (adjusted difference À0.7, 95% CI À1.6 to 0.3) and the calciumalone group (À1.6, À2.6 to À0.6). But, the difference was statistically significant only in the calcium-alone group. There was no significant difference between the two intervention groups regarding the pain intensity (0.9, À0.4 to 1.8) (Table 2, Figure 2 ).
In terms of menstrual blood loss score, no significant differences were found between none of the groups (calcium-vitamin D vs. placebo À7.7, À32.0 to 16.7), Figure 3 ).
We also compared the three groups in terms of percent change of pain intensity (change from baseline divided by baseline values). Mean percent reduction in the calcium-vitamin D group was 20%, in calcium-alone group was 32% and in the placebo group was 6%. The results of group comparisons were similar with abovementioned results. Compared to the placebo group, mean percent reduction of pain intensity was higher in both the calcium-vitamin D group (adjusted difference 14%, 95% CI À2% to 32%) and calcium-alone group (26%, 10% to 42%), and the difference was only statistically significant in the calcium-alone group. There was no statistically significant difference between the two intervention groups (À12%, À28% to 3%) (unplanned analysis).
With regard to quality of life components, there was an increase in mean of physical health and mental health post-intervention scores compared to pre-intervention in calcium-vitamin D group (mean difference 3.3 and 7.1, respectively), calcium-alone group (6.7 and 9.9), and only a slight change in the placebo group (0.6 and 1.0), but the differences among the groups were not statistically significant (Table 4 ). Figure 2 Mean score of pain intensity in the intervention and placebo groups at different cycles. SD, standard deviation; CI, confidence interval. Repeated Measures ANOVA (adjusted for multiple comparison using Sidak) was used for comparison of the groups adjusted for baseline value and daily calcium intake; Wilks' Lambda showed no significant effect of time (P ¼ 0.206) and interaction of time with group (P ¼ 0.330). Figure 3 Mean score of menstrual bleeding in the intervention and placebo groups at different cycles.
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In terms of satisfaction level with treatment, 16 (57%) in calcium-vitamin D group, 19 (66%) in calcium-alone, and 8 (29%) in placebo were satisfied or very satisfied with their treatments in the first intervention cycle. The figures were 17 (68%), 17 (63%), 9 (36%) in the second and 17 (70%), 19 (73%), and 6 (26%) in the third cycle, respectively (2-3 missed value in the second and 3-4 in the third cycle per group). Compared to placebo group, calcium-vitamin D group was significantly more satisfied with treatment in all first (P ¼ 0.005), second (P ¼ 0.001), and third (P < 0.001) cycles, and same applied to calcium-alone group in all first (P ¼ 0.006), second (P ¼ 0.003), and the third (P < 0.001) cycles. There were no significant differences between the two intervention groups in any of the cycles (not shown in tables).
Mean (SD) number of analgesics (Ibuprofen) used in the pre-intervention cycle, and the first, second, and third cycles, and the cycle following intervention, was 2. .7), and 2.4 (1.7) in placebo group. Despite a slight reduction in mean number of analgesics used in calcium-vitamin D and calcium-alone groups, no significant differences were observed between the groups (not shown in tables).
Frequency of reported side-effects gradually decreased with advancing intervention period. The most common side-effects included constipation and headache in the first cycle, as reported in moderate or severe forms by two and three participants, respectively, in calciumvitamin D group, and by five and three participants in the calcium-alone group. In the placebo group, one case of severe constipation and no moderate or severe headache was reported (Table 5) .
Discussion
In the present study, menstrual pain intensity was significantly reduced by supplementation of 1000 mg/day of calcium from 15th day of menstrual cycle until disappearance of dysmenorrhea symptoms in the following cycle, over three under-intervention cycles and one following cycle. Supplementation of combined calcium-vitamin D (1000 mg of calcium and 5000 IU of vitamin D3) did reduce pain intensity but the reduction was not statistically significant compared to placebo group. Neither calcium-vitamin D nor calcium-alone made any significant difference compared to placebo in terms of affecting on menstrual blood loss, physical, and mental health components of quality of life, and number of analgesics used.
It has been demonstrated that calcium ion is able to regulate capacity of muscle cells in response to nervous stimuli through various mechanisms. Increased calcium decreases neuromuscular stimulation, and reduced calcium leads to muscle spasm and contraction [11] .
In the earlier trial, we demonstrated efficacy of calcium consumption (600 mg/day) from the 15th day of the menstrual cycle until the end of menstrual pain in the following cycle in reducing menstrual pain intensity [16] and lack of a significant effect in reducing amount of menstrual blood loss [29] on the same population which is consistent with the present study results.
Negative association has been demonstrated between the daily intake of dairy products and prevalence and severity of dysmenorrhea in two cross-sectional studies in Jordan [15, 30] . In one study dysmenorrhea was significantly less common in students who consumed three or four servings of dairy products per day as compared to those who consumed no dairy products [15] . In the other study, participants with very severe dysmenorrheal pain reported significantly lower amount of dairy products intake as compared to those with severe dysmenorrheal pain [30] . Taking into account that more than 70% of dietary calcium is provided by dairy products [13] , results obtained in the above studies appear to be consistent with the present study results regarding the effect of calcium in reducing the pain intensity. On the contrary, in another cross-sectional study, a positive relationship was reported between consumption of dairy Health-related quality of life was assessed using SF-36 on the 7th day of the cycle prior to intervention cycles (baseline value) and the third under-intervention cycle. Data indicate mean (standard deviation); Range of score for both sub-scales: 0-100, the higher score, the better condition. One-way ANOVA was used for comparison of the groups before intervention and ANOVA after intervention adjusted for baseline value and daily calcium intake.
products and severity of dysmenorrhea [14] . Absence of control over possible confounding factors or recall bias in observational studies may be reasons for this inconsistency.
In this trial, although mean pain intensity was lower in the calcium-vitamin D group than in the placebo group, the difference was not significant. We found no study assessing effect of supplementation of combined calcium-vitamin D on dysmenorrhea. Results of two trials in Italy [17] and Iran [18] show that administration of single dose of 300 000 units of oral cholecalciferol 5 days before the onset of menstrual bleeding significantly reduced the intensity of severe dysmenorrhea, but the effect was not significant where the pain intensity was moderate (less than 7) [18] . We cannot say there is inconsistency between our and these two study results because we had no vitamin D-alone group and its administration may have no additional effect when there is an adequate calcium supplementation.
The lower, but statistically insignificant, mean pain intensity in the calcium-alone group compared to the combined calcium-vitamin D group may only be related to chance. Sample size and power of this study is not adequate to judge about equivalency of these two active interventions. Based on our study results, we may conclude that the vitamin D supplement has no additional beneficial effect on the pain intensity if an adequate calcium intake is guaranteed. No superior effect of combined calcium-vitamin D supplementation to calcium supplementation alone has also been shown in improving disturbed bone metabolism in patients with congestive heart failure [31] . No greater effect of addition of vitamin D to the calcium supplementation may also be related to high (about two third) proportion of participants with baseline pain intensity of less than 7 in our study.
Review of literature revealed no study on the effect of dietary or medical supplementation of vitamins on quality of life in women with dysmenorrhea. The sense of satisfaction with life is weaker in people with severe menstrual pain compared to those with no menstrual pain. This pain affects health-related quality of life in those with primary dysmenorrhea [32] . Interventions for reducing severity of dysmenorrhea seem to have positive effect on quality of life. In a clinical trial conducted in Turkey, a significant reduction in menstrual pain with subsequent increase in quality of life was observed as a result of home exercise in women with dysmenorrhea [33] . In the present study, increase in mean score of the health-related quality of life after intervention in intervention groups (especially in calcium-alone group) was higher compared to placebo, although the difference was not significant. Also, significantly higher proportion of those who received the treatment methods were satisfied with the method used as compared to those received placebo.
Although this study did not find any significant adverse effects of the two treatments regimes, the number of participants and duration of intervention in this study was not large enough to draw any conclusions about the adverse effects.
Because of some limitations, this study was not planned to test superiority of combination of vitamin D and calcium compared to calcium-alone due to need for higher sample size to test such a hypothesis. Hence, this study should be considered as only a pilot study in this area and trials with higher sample size are needed to test the superiority. However, based on this study results it seems that the addition of vitamin D to calcium supplementation has limited justification for women with dysmenorrhea because there are some concerns of an increase in LDL-C [34] and total cholesterol [35] following treatment with vitamin D.
Strong points of the present study include preventing potential bias in various ways such as blinding participants and people involved in the recruitment and/or data collection. Assessing menstrual pain intensity, bleeding, and quality of life prospectively in the one cycle run-in period, follow-up of participants one cycle following intervention to assess persistence of intervention effect, recording side-effects in the diary and measuring mean daily consumption of calcium using FFQ, and low (only one) participant withdrawal can be considered as other strengths of this study.
Due to financial limitations, we had no laboratory assessment of calcium and vitamin D status in participants before and after intervention and no assessment of effect of the intervention on other biochemical parameters. This can be considered as a limitation for this study, especially for its generalizability, because the intervention effects may be influenced by baseline level of calcium and vitamin D. However, assessing dietary calcium using FFQ and asking about length of sun exposure in this study showed high prevalence of deficiency of calcium and vitamin D intake in the study population. Therefore, the study results may not be generalizable to populations with suitable intake of calcium and vitamin D. Considering the restrictions of living in dormitory in terms of nutrition, exercise, etc., further studies should be conducted on other groups of women for generalizability of the results.
The no beneficial effect of addition of vitamin D on the pain relief may be related to the adequate (about 12-14 g a month) calcium supplementation in this study. Therefore, further research is needed to assess if supplementing adequate calcium would then change patients to non-responders to further supplementation.
Conclusion
The present study results confirm the effectiveness of supplementation of calcium-alone in reducing severity of primary dysmenorrhea. The same effect was not found by calcium-vitamin D supplementation. Moreover, none of the calcium-vitamin D or calcium-alone supplements showed any significant effects on amount of menstrual bleeding. Based on our results, calcium can be used for dysmenorrhea but we recommend not taking calciumvitamin D for this disorder due to no beneficial effect of addition of vitamin D to the supplement. However, further studies in various populations with assessment of biochemical parameters are needed for more precise conclusion on the supplement efficiency and safety.
